Literature DB >> 33822282

Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection.

Alison L Bailey1, Saif Al-Adwan2, Eliea Sneij3, Nicholas Campbell3, Matthew E Wiisanen4.   

Abstract

PURPOSE OF REVIEW: Hepatitis C virus (HCV) and atherosclerotic cardiovascular disease (ASCVD) are two diseases that affect millions around the globe. Hepatitis C affects more than 70 million individuals globally. ASCVD is commonly encountered and remains the top cause of death worldwide. A link has been identified between HCV and atherosclerosis. RECENT
FINDINGS: A review of recent studies which define the association between HCV infection and an increased risk of subclinical ASCVD and experiencing cardiovascular (CV) events. It is now recognized that there is an increased burden of atherosclerosis in individuals infected with HCV that translates into increased cardiovascular events. An increase in the number of diagnosed cases of HCV is expected as screening recommendations for the virus have expanded. Strategies to educate healthcare professionals about this increased CV risk will need to be considered as well as the optimal strategy to lower CV risk in this growing population.

Entities:  

Keywords:  Atherosclerosis, inflammation, Direct-acting antiviral; Cardiovascular disease; Hepatitis C virus

Year:  2021        PMID: 33822282     DOI: 10.1007/s11886-021-01475-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  20 in total

Review 1.  High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis.

Authors:  Christophe Meune; Emmanuel Touzé; Ludovic Trinquart; Yannick Allanore
Journal:  Arch Cardiovasc Dis       Date:  2010-05-18       Impact factor: 2.340

Review 2.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Authors:  Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson
Journal:  Hepatology       Date:  2018-11-06       Impact factor: 17.425

3.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

Review 4.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

Review 5.  Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection.

Authors:  Ulrich Spengler
Journal:  Pharmacol Ther       Date:  2017-10-10       Impact factor: 12.310

Review 6.  Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy.

Authors:  Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Marcella Visentini; Maurizio Tonizzo; Valter Gattei; Pietro Andreone; Gabriele Pozzato
Journal:  Autoimmun Rev       Date:  2020-06-12       Impact factor: 9.754

Review 7.  [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].

Authors:  D Bonnefont-Rousselot
Journal:  Ann Pharm Fr       Date:  2015-10-21

8.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

9.  Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018.

Authors:  A Blythe Ryerson; Sarah Schillie; Laurie K Barker; Benjamin A Kupronis; Carolyn Wester
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-10       Impact factor: 17.586

10.  Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.

Authors:  Kuan Ken Lee; Dominik Stelzle; Rong Bing; Mohamed Anwar; Fiona Strachan; Sophia Bashir; David E Newby; Jasmit S Shah; Michael H Chung; Gerald S Bloomfield; Chris T Longenecker; Shashwatee Bagchi; Shyamasundaran Kottilil; Sarah Blach; Homie Razavi; Peter R Mills; Nicholas L Mills; David A McAllister; Anoop S V Shah
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.